How to Get Jardiance in Delaware: Prescriptions, Telehealth, and Pharmacy Access

What Is Jardiance and Why Delaware Patients Are Seeking It

Empagliflozin (brand name Jardiance) is an FDA-approved sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by Boehringer Ingelheim and Eli Lilly. It blocks glucose reabsorption in the proximal renal tubule, lowering blood glucose, blood pressure, and intraglomerular pressure simultaneously. Delaware patients request it for three distinct FDA-approved reasons: type 2 diabetes mellitus, symptomatic heart failure, and chronic kidney disease with or without diabetes.

The FDA first approved empagliflozin in August 2014 for type 2 diabetes management. Subsequent approvals followed for heart failure with reduced ejection fraction (HFrEF) in 2021 and heart failure with preserved ejection fraction (HFpEF) in 2022, and for CKD in 2023. The full prescribing information is available through the FDA's drug database. [1]

Interest in Jardiance accelerated after the EMPA-REG OUTCOME trial (N=7,020) published in the New England Journal of Medicine in 2015 demonstrated a 38% relative reduction in cardiovascular death among adults with type 2 diabetes and established cardiovascular disease who received empagliflozin versus placebo (3.7% vs. 5.9%, P<0.001). [2] That single finding shifted prescribing patterns nationally, including in Delaware, where cardiovascular disease remains a leading cause of mortality. [3]

The EMPEROR-Reduced trial (N=3,730) then showed a 25% relative risk reduction in the composite of cardiovascular death or hospitalization for heart failure with empagliflozin 10 mg versus placebo (hazard ratio 0.75 to 95% CI 0.65 to 0.86, P<0.001). [4] For CKD, the EMPA-KIDNEY trial (N=6,609) reported a 28% lower risk of kidney disease progression or cardiovascular death with empagliflozin versus placebo (hazard ratio 0.72 to 95% CI 0.64 to 0.82, P<0.001). [5]

These outcomes data explain why endocrinologists, cardiologists, and nephrologists across Delaware increasingly write empagliflozin prescriptions for patients who previously might have received an older drug class with fewer cardiovascular or renal benefits.

Who Can Prescribe Jardiance in Delaware

In Delaware, empagliflozin is a Schedule-uncontrolled prescription drug, meaning any licensed prescriber with Delaware DEA registration and prescriptive authority may write for it. That includes MDs, DOs, nurse practitioners (APRNs), and physician assistants (PAs). Delaware's APRN practice act (Title 24, Chapter 19 of the Delaware Code) grants full prescriptive authority to APRNs without a mandatory physician co-signature, making telehealth NP-led practices a legitimate route for Delaware patients. [6] PAs in Delaware operate under a supervising physician agreement but retain broad prescriptive authority.

The American Diabetes Association's 2024 Standards of Care explicitly recommend SGLT2 inhibitors for patients with type 2 diabetes who have established cardiovascular disease, heart failure, or CKD with albuminuria, regardless of HbA1c level. [7] That guideline language means a PA or NP reviewing your chart can initiate Jardiance without specialist referral if your records document one of those conditions.

A prescriber's minimum clinical assessment before issuing a Jardiance prescription typically includes:

• Confirmation of a qualifying diagnosis (T2D, HF, or CKD)
• Review of current eGFR (Jardiance is not recommended when eGFR is <20 mL/min/1.73 m² in the CKD indication, and glucose-lowering benefit diminishes when eGFR falls below 30)
• Blood pressure and volume status assessment (SGLT2 inhibitors carry a small risk of hypotension)
• Urinalysis to check for active urinary tract infection, which is a contraindication to initiation

How to Get a Jardiance Prescription in Delaware: Step-by-Step

Getting a Jardiance prescription in Delaware follows a straightforward sequence regardless of whether you choose an in-person or telehealth route.

Step 1. Choose a prescriber type. Delaware-licensed MDs, DOs, APRNs, and PAs can all prescribe empagliflozin. Telehealth platforms that hold a Delaware telehealth registration may conduct an asynchronous or synchronous visit and issue an electronic prescription to any Delaware-licensed pharmacy.

Step 2. Gather your records. Collect your most recent HbA1c (within 6 months for T2D patients), eGFR and serum creatinine (within 3 months is preferable), echocardiogram or cardiology notes (for heart failure patients), and a list of current medications. Bringing these to your appointment shortens the visit and avoids a prescriber ordering duplicative labs.

Step 3. Complete the clinical visit. For telehealth, most platforms schedule a video or asynchronous intake visit of 15 to 30 minutes. The prescriber confirms your diagnosis, reviews contraindications (including recurrent urinary tract infections, recurrent genital mycotic infections, or a history of diabetic ketoacidosis), and discusses goals. The FDA label lists euglycemic diabetic ketoacidosis as a serious adverse event even in patients with normal glucose; patients planning major surgery or prolonged fasting should stop empagliflozin at least 3 days prior. [1]

Step 4. Receive and fill the prescription. The prescriber sends an e-prescription to your chosen pharmacy. Mail-order pharmacies licensed in Delaware can ship within 2 to 5 business days after a prescription is received. Retail pharmacies typically stock 10 mg and 25 mg tablets in 30-count bottles.

Step 5. Address insurance or prior authorization. If your plan requires a PA (Delaware Medicaid and most commercial plans do), your prescriber's office initiates the PA request. See the prior authorization section below for documentation details.

Labs Required Before Starting Jardiance in Delaware

Lab requirements are not arbitrary. They reflect the drug's renal mechanism and safety profile. Delaware prescribers following the ADA 2024 Standards of Care and the 2022 AHA/ACC/HFSA Heart Failure Guideline will routinely check: [7][8]

• eGFR and serum creatinine. The FDA label states that empagliflozin is not recommended when eGFR is <20 mL/min/1.73 m² for the CKD indication. For glucose lowering in T2D, the benefit diminishes below eGFR 30. Most Delaware prescribers want a result dated within 3 months. [1]
• Serum potassium. SGLT2 inhibitors cause mild potassium-sparing relative to loop diuretics; in patients already on ACE inhibitors or ARBs, a baseline potassium is prudent.
• HbA1c. Required for T2D-indication prescriptions to document glycemic status and establish a baseline for follow-up.
• Urinalysis with culture (if symptomatic). Active urinary tract infection contraindicates initiation. Asymptomatic bacteriuria alone is not a contraindication per the FDA label, but most Delaware clinicians treat it first. [1]
• Liver function tests (LFTs). Not mandatory, but many telehealth platforms include a comprehensive metabolic panel that captures LFTs given the small reported risk of hepatocellular injury in post-marketing surveillance. [9]

Quest Diagnostics and LabCorp both operate collection sites throughout Delaware, including in Wilmington, Dover, and Newark. Most telehealth platforms issue lab orders electronically to these chains, and results are returned digitally within 24 to 72 hours.

Telehealth Prescribing for Jardiance in Delaware

Delaware permits telehealth prescribing for non-controlled prescription drugs, including empagliflozin. The Delaware Health and Social Services telemedicine policy, aligned with HB 110 (signed 2017) and updated COVID-era flexibilities that were made permanent in 2023, allows a licensed Delaware provider to conduct an initial prescribing visit via video without a prior in-person relationship. [6]

This matters practically: a Delaware resident in Sussex County, where specialist access is thinner than in New Castle County, can see a board-certified endocrinologist or cardiologist by video the same week and receive an e-prescription within hours of that visit.

Telehealth platforms operating in Delaware typically request the following before scheduling your prescribing visit:

1. A photo ID confirming Delaware residency
2. Your insurance card (if using insurance)
3. PDF or image upload of recent lab results
4. A completed medical history intake form

Platforms that hold a Delaware telehealth registration must comply with Delaware's patient-privacy regulations and the federal 21st Century Cures Act, which includes electronic health record interoperability requirements. [10] That means your prescriber's platform should be able to send visit notes to your primary care physician if you authorize it.

A 2023 analysis in JAMA Internal Medicine (N=118,492) found that telehealth visits for cardiometabolic conditions resulted in prescription rates comparable to in-person visits, with no significant difference in 90-day adherence rates (relative risk 0.98 to 95% CI 0.96 to 1.01). [11] Telehealth is not a lesser pathway; it is a parallel one.

Prior Authorization for Jardiance Under Delaware Insurance Plans

Delaware Medicaid (Diamond State Health Plan and DMAP fee-for-service) covers empagliflozin with prior authorization. The typical PA criteria for Delaware Medicaid require: [12]

• A documented diagnosis of T2D (ICD-10 E11.x), heart failure (I50.x), or CKD (N18.x)
• Confirmation that eGFR is in the range supported by the prescribed indication
• For T2D, documentation that metformin is contraindicated or not tolerated, OR that the patient has established ASCVD, HF, or CKD (which allows Jardiance as a first-line add-on per ADA 2024 guidelines) [7]
• A prescriber attestation confirming the clinical indication

Most Delaware Medicaid PA requests are processed within 3 to 14 business days. Urgent PA requests, submitted when a prescriber documents clinical urgency, may be processed within 72 hours under Delaware Medicaid managed care organization (MCO) rules. [12]

For commercial insurance, United Healthcare Delaware, Highmark Blue Cross Blue Shield Delaware, and Aetna Delaware all include empagliflozin on their formularies, typically at Tier 3 or Tier 4 with PA requirements mirroring the Medicaid criteria above. Patients on the Boehringer Ingelheim Jardiance Savings Card may pay as little as $10 per 30-day fill if commercially insured and eligible. [13]

The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, an SGLT2 inhibitor with proven benefit should be recommended independent of baseline HbA1c." [7] Printing this language and attaching it to a PA appeal is clinically sound practice.

Transferring a Jardiance Prescription to Delaware

Patients relocating to Delaware, or those who establish care with a new Delaware provider while keeping an out-of-state prescription, have two clean options.

Option A: Transfer the existing prescription. Delaware pharmacies can accept transferred prescriptions for non-controlled drugs from out-of-state pharmacies. The receiving Delaware pharmacist contacts the originating pharmacy directly. Refills remaining on the original prescription transfer with it. Federal law limits each prescription transfer to one time per pharmacy. [14]

Option B: Obtain a new prescription from a Delaware-licensed prescriber. A telehealth visit confirms your existing diagnosis and generates a Delaware-issued prescription. This is often faster than a transfer if the originating pharmacy is slow to respond. Most telehealth platforms can complete this in one same-day or next-business-day visit.

Mail-order pharmacies licensed in Delaware, including CVS Caremark, Express Scripts (Cigna), and OptumRx, ship empagliflozin statewide. Wilmington-area retail options include multiple CVS, Walgreens, and Rite Aid locations, as well as independent pharmacies in Dover and Georgetown.

503A Compounding Pharmacies and Empagliflozin in Delaware

Delaware-licensed 503A compounding pharmacies can compound empagliflozin for individual patients when a prescriber determines that the commercially available product does not meet a specific patient need. This is a narrow pathway. The FDA has not placed empagliflozin on its list of bulk drug substances approved for 503A compounding, which means a 503A pharmacy may compound from a commercially available finished dosage form only in very limited circumstances. [15]

In practical terms, the vast majority of Delaware patients will receive the FDA-approved Jardiance tablet rather than a compounded product. Compounding is typically relevant only when a patient requires a dose form not commercially available, such as an oral suspension for a patient with a swallowing disorder, and when the prescriber can document the medical necessity.

Patients should confirm that any 503A pharmacy claiming to compound empagliflozin holds a current Delaware Board of Pharmacy license and complies with USP Chapter 795 standards for non-sterile compounding. The Delaware Board of Pharmacy license lookup is publicly available on the Division of Professional Regulation website. [16]

Side Effects Delaware Prescribers Discuss Before Starting Jardiance

Delaware prescribers are expected to counsel patients on the following before initiating empagliflozin, consistent with the FDA-approved labeling: [1]

• Urinary tract infections and genital mycotic infections. EMPA-REG OUTCOME reported genital mycotic infections in 6.4% of women and 3.1% of men on empagliflozin versus 1.8% and 0.4% respectively on placebo. [2]
• Volume depletion and hypotension. Patients on diuretics or with baseline low blood pressure require closer monitoring in the first 4 weeks.
• Euglycemic diabetic ketoacidosis. Blood glucose may be normal or near-normal during this serious adverse event. Patients should seek emergency care for nausea, vomiting, abdominal pain, fatigue, or difficulty breathing even if their glucometer reads <180 mg/dL. [1]
• Lower limb amputation risk. The CANVAS trial (N=10,142) for canagliflozin raised amputation signals for that drug; subsequent analyses have not demonstrated the same risk for empagliflozin, but the FDA label retains a class-wide discussion, and prescribers assess peripheral vascular disease and foot ulcers at baseline. [17]
• Fournier's gangrene. A rare but severe necrotizing fasciitis of the genitalia and perineum has been reported post-marketing across the SGLT2 inhibitor class. [1]

The EMPEROR-Preserved trial (N=5,988) confirmed that empagliflozin's cardiovascular benefit extends to HFpEF patients (hazard ratio 0.79 for the primary composite, 95% CI 0.69 to 0.90, P<0.001), which is a population historically underserved by proven pharmacotherapy. [18] Delaware cardiologists managing HFpEF patients should weigh this benefit against the side-effect profile for each individual.

Cost and Coverage Summary for Delaware Patients

| Coverage type | Expected monthly cost | PA required | |---|---|---| | Delaware Medicaid (DMAP/Diamond State) | $0 to $10 copay | Yes | | Commercial insurance (Tier 3) | $30 to $90 copay | Usually yes | | Commercial insurance with BI savings card | $10 copay | Yes (insurance must be commercial) | | Medicare Part D | $35 to $100+ depending on plan phase | Varies by plan | | Uninsured, cash pay | $400 to $550 per 30 tablets | No PA needed |

Medicare patients who hit the catastrophic coverage phase pay 5% of drug costs under the Inflation Reduction Act 2023 changes, which cap out-of-pocket Part D costs at $2,000 per year beginning in 2025. [19] This cap benefits Delaware seniors taking Jardiance as a long-term cardiovascular or renal therapy.